534
We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.
 3 patients with lymphoproliferative disorders: Subject; 3: Subject.Population; acute coronary syndromes: Effect; their initial infusion of rituximab: Treatment; lymphoproliferative disorders: Treatment.Disorder; rituximab: Treatment.Drug; infusion: Treatment.Route
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 3 patients with lymphoproliferative disorders: Subject; 3: Subject.Population; acute coronary syndromes: Effect; their initial infusion of rituximab: Treatment; lymphoproliferative disorders: Treatment.Disorder; rituximab: Treatment.Drug; infusion: Treatment.Route